{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:59:18Z","timestamp":1792569558325,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"9-10","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.drudis.2011.12.010","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T10:47:07Z","timestamp":1324032427000},"page":"409-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)"],"prefix":"10.1016","volume":"17","author":[{"given":"Boris","family":"Cvek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2011.12.010_bib0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd3473","article-title":"Could pharma open its drug freezers?","volume":"10","author":"Mullard","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2011.12.010_bib0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrd3461","article-title":"Mining for the therapeutic gold","volume":"10","author":"Collins","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2011.12.010_bib0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2011.12.010_bib0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2011.12.010_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J. Health Econ."},{"key":"10.1016\/j.drudis.2011.12.010_bib0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2011.12.010_bib0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jme.2002.000786","article-title":"Are patents for methods of medical treatment contrary to the ordre public and morality or \u2018generally inconvenient\u2019?","volume":"30","author":"Minovetski","year":"2004","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.drudis.2011.12.010_bib0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2011.12.010_bib0045","first-page":"503","article-title":"Unpatentable drugs and the standards of patentability","volume":"87","author":"Roin","year":"2009","journal-title":"Texas Law Rev."},{"key":"10.1016\/j.drudis.2011.12.010_bib0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/wsbm.147","article-title":"Drug repurposing and adverse event prediction using high-throughput literature analysis","volume":"3","author":"Deftereos","year":"2011","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.drudis.2011.12.010_bib0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/0022-3859.81870","article-title":"Drug repositioning: re-investigating existing drugs for new therapeutic indications","volume":"57","author":"Padhy","year":"2011","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.drudis.2011.12.010_bib0060","doi-asserted-by":"crossref","first-page":"E1000208","DOI":"10.1371\/journal.pmed.1000208","article-title":"Are patents impeding medical care and innovation?","volume":"7","author":"Gold","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.drudis.2011.12.010_bib0065","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jnci\/djp177","article-title":"How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question","volume":"101","author":"Fojo","year":"2009","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.drudis.2011.12.010_bib0070","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1377\/hlthaff.24.4.1057","article-title":"Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world","volume":"24","author":"Hale","year":"2005","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drudis.2011.12.010_bib0075","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.trstmh.2008.09.008","article-title":"Paromomycin","volume":"103","author":"Davidson","year":"2009","journal-title":"Trans. R. Soc. Trop. Med. Hyp."},{"key":"10.1016\/j.drudis.2011.12.010_bib0080","first-page":"331","article-title":"Visceral leishmaniasis (kala-azar): challenges ahead","volume":"123","author":"Singh","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.drudis.2011.12.010_bib0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-3156.2010.02516.x","article-title":"The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India","volume":"15","author":"Sarnoff","year":"2010","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.drudis.2011.12.010_bib0090","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2011.12.010_bib0095","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/ijc.25237","article-title":"Antabuse (disulfiram) as a pilot case of nonprofit drug","volume":"127","author":"Cvek","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drudis.2011.12.010_bib0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ijc.25779","article-title":"Antabuse repurposing: we need more knowledge and wide international support","volume":"129","author":"Cvek","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drudis.2011.12.010_bib0105","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1126\/science.331.6024.1540-a","article-title":"Cancer research and the $90 billion metaphor","volume":"331","author":"Marshall","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.drudis.2011.12.010_bib0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp0708307","article-title":"\u2018Westernizing\u2019 women's risks? Breast cancer in low-income countries","volume":"358","author":"Porter","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2011.12.010_bib0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(11)70031-6","article-title":"Optimization of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus 2010","volume":"12","author":"Anderson","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2011.12.010_bib0120","series-title":"The Guide to Off-Label Prescription Drugs: New Uses for FDA-Approved Prescription Drugs","author":"Loughlin","year":"2006"},{"key":"10.1016\/j.drudis.2011.12.010_bib0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.1837","article-title":"Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm","volume":"29","author":"Wicks","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2011.12.010_bib0130","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1169920","article-title":"Repurposing with a difference","volume":"324","author":"Boguski","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drudis.2011.12.010_bib0135","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.drudis.2008.05.003","article-title":"The value of proteasome inhibition in cancer. Can the old drug, disulfiram, has a bright new future as a novel proteasome inhibitor?","volume":"13","author":"Cvek","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2011.12.010_bib0140","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/156800911794519806","article-title":"Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome","volume":"11","author":"Cvek","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2011.12.010_bib0145","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2011.12.010_bib0150","first-page":"3040","article-title":"Inhibition of N-n-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in rats by administration of disulfiram in the diet","volume":"39","author":"Irving","year":"1979","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2011.12.010_bib0155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/carcin\/4.5.617","article-title":"The effect of disulfiram on the carcinogenecity of N-butyl-N-(3-carboxypropyl)nitrosamine in the rat","volume":"4","author":"Irving","year":"1983","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drudis.2011.12.010_bib0160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/carcin\/8.9.1309","article-title":"Influence of disulfiram on the metabolism of the urinary bladder carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine","volume":"8","author":"Irving","year":"1987","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drudis.2011.12.010_bib0165","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","article-title":"Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2011.12.010_bib0170","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1021\/jm8007807","article-title":"Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells","volume":"51","author":"Cvek","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2011.12.010_bib0175","first-page":"47","article-title":"Spontaneous regression of breast cancer","volume":"12","author":"Lewison","year":"1977","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.drudis.2011.12.010_bib0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01877380","article-title":"Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study","volume":"6","author":"Dufour","year":"1993","journal-title":"Biotherapy"},{"key":"10.1016\/j.drudis.2011.12.010_bib0185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev.pa.21.040181.003043","article-title":"The actions and metabolic fate of disulfiram","volume":"21","author":"Eneanya","year":"1981","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2011.12.010_bib0190","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1126\/science.7071604","article-title":"Human aldehyde dehydrogenase: mechanism of inhibition of disulfiram","volume":"216","author":"Vallari","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.drudis.2011.12.010_bib0195","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(88)90184-5","article-title":"Randomized, double-blind, placebo-controlled trial of ditiocarb sodium (Imuthiol) in human immunodeficiency virus infection","volume":"332","author":"Lang","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2011.12.010_bib0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0140-6736(90)90802-C","article-title":"Inhibition of HIV progression by ditiocarb. German DTC study group","volume":"335","author":"Reisinger","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2011.12.010_bib0205","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/jama.1991.03460120052035","article-title":"Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study","volume":"265","author":"Hersh","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2011.12.010_bib0210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157016209788348038","article-title":"Failure of ditiocarb (diethyldithiocarbamate) therapy: was diet the reason?","volume":"7","author":"Cvek","year":"2009","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.drudis.2011.12.010_bib0215","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0304-4165(97)00027-5","article-title":"The origin of an EPR signal observed in dithiocarbamate-loaded tissues. Copper(II)-dithiocarbamate complexes account for the narrow hyperfine lines","volume":"1335","author":"Suzuki","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drudis.2011.12.010_bib0220","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/1535-7163.1049.3.9","article-title":"Disulfiram inhibits activating transcription factor\/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease","volume":"3","author":"Brar","year":"2004","journal-title":"Mol. Cancer Ther."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644611004375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644611004375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:10:37Z","timestamp":1761221437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644611004375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":44,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1359644611004375"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2011.12.010","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2011.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}